俺自己胆小, 早就撤退了,现在只有眼馋的份了。
http://www.google.com/finance?q=NASDAQ:VVUS
[size=2.6em]10.55[size=1.8em]0.00 (0.00%)
Pre-market: 22.21 +11.66 (110.52%)Feb 23, 6:06AM EST [size=0.85em]NASDAQ real-time data - DisclaimerCurrency in USD
Vivus, Inc. (VVUS) stock climbed 100.47 percent to $21.15 in aftermarket trading session. The company announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults. The Committee voted 20 to 2, on the recommendation for an approval based on a favorable benefit-risk profile.Vivus, Inc. (VVUS) stock climbed 100.47 percent to $21.15 in aftermarket trading session. The company announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults. The Committee voted 20 to 2, on the recommendation for an approval based on a favorable benefit-risk profile.
|